Compare Sanofi SA (SNY) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Sanofi SA trades at $40.1 (market cap $95.18B), while YieldMax Universe Fund of Option Income ETFs trades at $7.62 (market cap $364M). The key difference: Sanofi SA is far larger — about 261.5× YieldMax Universe Fund of Option Income ETFs's market cap, and Sanofi SA pays a 6.01% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and YieldMax Universe Fund of Option Income ETFs for 55 Days on average.
| SNY | YMAX | |
|---|---|---|
Market Cap | $95.18B | $364M |
Volume | 2,995,646 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $52.34 | $12.98 |
52-Week Low | $39.51 | $7.27 |
Typical Hold Time | 94 Days | 55 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
YMAX trades at $7.53, down 1.83% on the day, with a bearish technical signal from moving averages. The ETF maintains weekly dividend distributions but faces concerns about NAV erosion and sustainability. Recent portfolio adjustments aim to address performance issues, though the fund's structure as a fund-of-funds adds additional cost layers that impact returns.
The outlook remains cautious due to structural concerns and persistent share price decline despite high yield. Investment opportunity exists for income-focused investors willing to accept principal erosion risks, while the primary risk involves unsustainable distribution policy and compounding fees affecting long-term total returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
